RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—nivolumab, which helps the immune system attack cancer, and ASTX727, which targets abnormal cells—can shrink or stabilize B-cell lymphomas that have returned or stopped responding to standard treatments. About 32 adult…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:29 UTC
-
Vitamin c boost: could high doses make chemo work better for tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C to standard chemotherapy can help treat blood cancers like lymphoma and chronic myelomonocytic leukemia (CMML) that have returned or not responded to treatment. About 80 adults will receive the combination therapy. The goal is t…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 06:23 UTC
-
Radioactive antibody combo aims to beat back stubborn hodgkin lymphoma
Disease control Recruiting nowThis study tests a new approach for people with Hodgkin lymphoma that has returned or not responded to treatment. It combines a radioactive antibody (Y-90 anti-CD25) with standard chemotherapy (BEAM) before a stem cell transplant. The goal is to see if this combination improves h…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Immune boosting cells show promise in fighting blood cancers after transplant
Disease control Recruiting nowThis study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC